Lung Cancer Mutation Panel (EGFR, KRAS, ALK)
Test Code
CPT coding may differ dependent on payer rules which may impact prior authorization testing.
Please direct any questions regarding CPT coding to the payer being billed.
Clinical Significance
Lung Cancer Mutation Panel (EGFR, KRAS, ALK) - This panel is comprised of mutational analysis of the EGFR and KRAS genes and assessment for ALK locus rearrangement using an FDA-cleared FISH assay. These are the most common tumor-associated genetic changes that have been shown to have prognostic and therapeutic consequences in non-small cell lung cancer (NSCLC) and help guide therapy. Patients with EGFR mutations are generally responsive to EGFR-directed kinase inhibitors, whereas those with evidence of ALK gene rearrangements are candidates for treatment with the ALK inhibitor crizotinib. The presence of KRAS mutation in lung adenocarcinoma predicts for non-response to kinase inhibitors and for tumors with inferior outcome.
Test Resources
Test Details
KRAS Mutation Analysis
FISH, ALK 2p23 Rearrangement, Lung Cancer (NSCLC)
Methodology
Reference Range(s)
| EGFR Mutation | Not detected |
| KRAS Mutation | Not detected |
| FISH, ALK 2p23 Rea, Lung Cancer (NSCLC) | See Laboratory Report |
Alternative Name(s)
Preferred Specimen(s)
Formalin-fixed, paraffin-embedded tissue
Alternative Specimen(s)
12 unstained charged (+) slides
Minimum Volume
8 unstained charged (+) slides
Collection Instructions
Do not reject specimens. Send to laboratory for screening.
Transport Container
Formalin-fixed, paraffin embedded tissue block
Transport Temperature
Room temperature
Specimen Stability
- Room temperature: 5 years
- Refrigerated: 5 years
- Frozen: Unacceptable
Setup Schedule
Do not reject specimens. Send to laboratory for screening.
Refrigerated: 5 years
Frozen: Unacceptable